Introduction

Overview of centronuclear myopathy (CNM)

Centronuclear myopathy (CNM) refers to a group of rare inherited muscle disorders characterised by weakness of the skeletal muscles. This arises from a distinctive abnormality in muscle cell structure, wherein the nucleus of the muscle cell is positioned in the centre, rather than its typical location at the periphery of the fibre cell.¹ These conditions are often observed early in infancy or childhood, but can also present later in life. CNM affects muscles responsible for voluntary movements, which often leads to difficulties with mobility and coordination.¹ 

Why understanding muscle cell membrane and T-tubule defects matters

Recent scientific discoveries have highlighted the importance of subcellular architecture in CNM pathology. In particular, defects in membrane trafficking and the structural integrity of transverse tubules (T-tubules) have emerged as central to the development of CNM.² This article explores these mechanisms in deeper detail.

The muscle cell’s architecture

Muscle structure

The majority of the muscles in the human body are classified as skeletal muscles, which are striated in appearance and attach to our bones via tendons, allowing us to initiate voluntary movements.³

Skeletal muscle fibres are highly specialised, elongated, cylindrical cells with a complex internal organisation designed to facilitate rapid and coordinated contraction. Each fibre contains multiple nuclei, normally located at the edges of the cell, and is packed with myofibrils, which are the contractile units.³

The role of T-tubules

T-tubules are invaginations of the skeletal muscle cell membrane that penetrate into the interior of muscle cells. Their primary function is to transmit electrical signals ( known as action potentials) from the surface to deep within the cell, ensuring that contraction occurs uniformly throughout the fibre. They work closely with the sarcoplasmic reticulum, a structure which stores calcium ions needed for muscle contraction. Together, these work to ensure voluntary movement of limbs.³

Membrane trafficking in muscle cells

Membrane trafficking refers to the movement of products such as proteins and lipids within the cell, especially those involved in vesicle formation, transport, and fusion. This system maintains cellular organisation, enables recycling of components, and supports the function and structure of the specialised structures like T-tubules.³

T-tubule defects in centronuclear myopathy

In CNM, T-tubules are often malformed or absent. This disruption leads to impaired excitation-contraction coupling, the process by which an electrical signal leads to muscle contraction. This defect contributes directly to muscle weakness, one of the primary symptoms of CNM.

Gene mutations and disruption of T-tubule formation

Mutations in several genes that encode proteins involved in shaping membranes and forming T-tubules have been associated with the pathology of CNM. These include:

MTM1: Encodes myotubularin, a molecule involved in regulating lipid signalling, essential for maintaining the curved structure of cell membranes.⁴

BIN1 (Amphiphysin-2): Plays a critical role in bending membranes to form tubules⁴

DNM2 (Dynamin-2): Involved in severing membrane vesicles from larger membranes, facilitating trafficking and T-tubule maintenance⁴

When any of these proteins malfunction due to genetic mutations, T-tubule formation is impaired⁴

Histological findings

Microscopic examination of muscle biopsies from CNM patients frequently reveals centralised nuclei, disorganised T-tubules, and abnormal triad structures (where T-tubules and the sarcoplasmic reticulum meet). These findings support the role of structural disorganisation in disease pathology.⁵

The consequences of this disorganisation result in impaired excitation-contraction coupling and progressive muscle weakness.

Membrane trafficking defects in CNM

While the structural breakdown of T-tubules is a visible biomarker, the underlying cause often lies in defective membrane trafficking. Normal trafficking ensures that proteins and lipids are delivered to the right places at the right times within the muscle cell.

What goes wrong

In CNM, mutations impair the ability of vesicles to form properly, navigate the cytoplasm, or fuse with their target membranes. This results in a cascade of failures, including mislocalization of membrane proteins, inadequate recycling of signalling receptors, as well as improper assembly of organelles like T-tubules. These defects not only contribute to structural abnormalities but also impair the cell’s ability to respond to stress, maintain energy levels, and regulate ion homeostasis.^2,4

Link to T-tubule integrity

The formation and maintenance of T-tubules depend on precisely regulated membrane trafficking. Proteins such as BIN1 and MTM1 interact physically and functionally to orchestrate the remodelling of membranes into the tubular networks essential for muscle function. Disruption of these interactions results in fragmented or flattened T-tubules, further weakening the excitation-contraction process.²

Key molecular players

A deeper understanding of the individual roles of proteins mutated in CNM sheds light on the disease mechanism and potential treatment targets.

MTM1 (Myotubularin)

This protein regulates the levels of certain lipids (phosphoinositides) that control membrane dynamics. Without functional MTM1, these lipids accumulate, leading to membrane instability and abnormal organelle formation.⁴

BIN1 (Amphiphysin-2)

BIN1 contains specialised domain features which allow it to bind to and bend membranes. It is crucial for T-tubule formation during muscle development and regeneration. Loss of BIN1 function leads to severe disorganisation of muscle fibers^4.

DNM2 (Dynamin-2)

Dynamin-2 has a key role in pinching off vesicles from membranes, a critical step in endocytosis and other trafficking pathways. Overactive or mutated forms of DNM2 can disrupt the balance of membrane remodelling, leading to both trafficking and structural defects.⁴

These molecules function as a network, and disruption at one point can lead to widespread effects on cellular integrity.

Therapeutic implications and future directions

Currently, no cure exists for CNM, and treatments are largely supportive. However, advances in understanding the molecular basis of the disease have opened new therapeutic avenues.

Gene replacement therapy 

Gene Replacement Therapy (GRT) is currently the most well-studied treatment option for CNM. AAV (adeno-associated virus) vectors have been used as a means to deliver functional genes to replace damaged ones in patients. For example,  MTM1 replacement in animal models has been shown to restore T-tubule structure and improve muscle function. Early-phase clinical trials also show challenges, such as immune responses and long-term expression remain.⁶

Future cell-based and pharmacological strategies

Research exploring stem cell therapies, small molecules that stabilise T-tubules, and drugs that enhance membrane repair or trafficking are currently in the works; however, more research is required to validate their potential.

Conclusion

Centronuclear myopathy is a complex disease involving defects in the cellular machinery of muscle cells. The characteristic impairments in membrane trafficking and T-tubule structure can explain many of the clinical symptoms and offer targets for innovative treatments. As science continues to expand our understanding of the intricate molecular interactions within muscle fibres, the prospects for meaningful therapies grow. The story of CNM illustrates how a detailed understanding of cell biology can illuminate pathways to healing even the most challenging inherited disorders.

Summary

• Centronuclear myopathy (CNM) is a rare inherited muscle disorder where muscle cell nuclei are abnormally positioned in the centre of fibres, causing progressive skeletal muscle weakness, often starting in infancy or childhood
• T-tubules, membrane invaginations that transmit electrical signals for muscle contraction, are often malformed or absent in CNM, leading to impaired excitation–contraction coupling and weakness
• Membrane trafficking defects, caused by mutations in key genes, disrupt the delivery and recycling of proteins and lipids, impairing T-tubule formation and maintenance
• Key genetic players include MTM1 (regulates lipid signalling for membrane stability), BIN1 (shapes membranes into tubules), DNM2 (severs vesicles for trafficking); mutations here cause structural and functional breakdown
• Histological features include centralised nuclei, disorganised T-tubules, and abnormal triad structures in muscle biopsies
• Therapeutic approaches in development include gene therapy (e.g., AAV delivery of MTM1), modulation of DNM2 activity, stem cell strategies, and drugs to stabilise T-tubules or restore membrane dynamics
• Challenges remain in delivering body-wide treatments, preventing immune reactions, ensuring safety in children, and addressing ethical and accessibility issues

Glossary 

• T-tubules: Tubular invaginations of the muscle cell membrane that help transmit electrical signals into the cell interior
• Excitation-contraction coupling: The physiological process by which an electrical stimulus leads to muscle contraction
• Membrane trafficking: The cellular process of moving proteins and lipids within the cell using vesicles
• Phosphoinositides: Lipid molecules involved in signalling and membrane dynamics
• Myotubularin (MTM1): An enzyme that regulates membrane lipids, mutations in which cause X-linked CNM
• Dynamin-2 (DNM2): A protein that facilitates vesicle scission from membranes
• Amphiphysin-2 (BIN1): A protein that shapes membranes into tubules, essential for muscle cell function